Brief: Immix Biopharma Receives FDA RMAT Designation For NXC-201
10/02/2025 15:15
Feb 10 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA RECEIVES FDA REGENERATIVE MEDICINE
ADVANCED
THERAPY (RMAT) DESIGNATION FOR NXC-201, STERICALLY-OPTIMIZED
CAR-T FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS
* IMMIX BIOPHARMA INC: ENROLLMENT IN NEXICART-2 STUDY
ACCELERATING; NEXT UPDATE PLANNED FOR H1 2025
Source text: ID:nGNXbjs757
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary